Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain.
Institute of Genetic Medicine, Centre for Life, Newcastle University, Newcastle NE1 3BZ, UK.
Dis Model Mech. 2018 Sep 21;11(9):dmm034397. doi: 10.1242/dmm.034397.
Endoglin is a transmembrane glycoprotein expressed in vascular endothelium that plays a key role in angiogenesis. Mutations in the endoglin gene () cause hereditary hemorrhagic telangiectasia type 1 (HHT1), characterized by arteriovenous malformations (AVMs) in different organs. These vascular lesions derive from abnormal processes of angiogenesis, whereby aberrant vascular remodeling leads to focal loss of capillaries. Current treatments for HHT1 include antiangiogenic therapies. Interestingly, a circulating form of endoglin (also known as soluble endoglin, sEng), proteolytically released from the membrane-bound protein and displaying antiangiogenic activity, has been described in several endothelial-related pathological conditions. Using human and mouse endothelial cells, we find that sEng downregulates several pro-angiogenic and pro-migratory proteins involved in angiogenesis. However, this effect is much reduced in endothelial cells that lack endogenous transmembrane endoglin, suggesting that the antiangiogenic activity of sEng is dependent on the presence of endogenous transmembrane endoglin protein. In fact, sEng partially restores the phenotype of endoglin-silenced endothelial cells to that of normal endothelial cells. Moreover, using an established neonatal retinal model of HHT1 with depleted endoglin in the vascular endothelium, sEng treatment decreases the number of AVMs and has a normalizing effect on the vascular phenotype with respect to vessel branching, vascular density and migration of the vascular plexus towards the retinal periphery. Taken together, these data show that circulating sEng can influence vascular development and AVMs by modulating angiogenesis, and that its effect on endothelial cells depends on the expression of endogenous endoglin.This article has an associated First Person interview with the first author of the paper.
内皮糖蛋白是一种表达于血管内皮的跨膜糖蛋白,在血管生成中发挥关键作用。内皮糖蛋白基因()的突变导致遗传性出血性毛细血管扩张症 1 型(HHT1),其特征是不同器官的动静脉畸形(AVMs)。这些血管病变源自血管生成的异常过程,其中异常的血管重塑导致毛细血管局灶性缺失。目前 HHT1 的治疗包括抗血管生成治疗。有趣的是,一种循环形式的内皮糖蛋白(也称为可溶性内皮糖蛋白,sEng),从膜结合蛋白中蛋白水解释放出来,并具有抗血管生成活性,已在几种与内皮相关的病理条件下被描述。使用人和鼠内皮细胞,我们发现 sEng 下调了几个参与血管生成的促血管生成和促迁移蛋白。然而,在缺乏内源性跨膜内皮糖蛋白的内皮细胞中,这种作用大大减弱,这表明 sEng 的抗血管生成活性依赖于内源性跨膜内皮糖蛋白的存在。事实上,sEng 部分恢复了沉默内皮糖蛋白的内皮细胞的表型,使其恢复为正常内皮细胞的表型。此外,使用血管内皮中内皮糖蛋白耗竭的已建立的新生儿视网膜 HHT1 模型,sEng 治疗可减少 AVM 的数量,并使血管表型正常化,表现为血管分支、血管密度和血管丛向视网膜边缘的迁移。总之,这些数据表明,循环 sEng 可以通过调节血管生成来影响血管发育和 AVMs,并且其对内皮细胞的作用取决于内源性内皮糖蛋白的表达。本文有一篇与第一作者的第一人称访谈。